Loading...
XNAS
ZVSA
Market cap3mUSD
Jun 06, Last price  
0.65USD
1D
1.50%
1Q
-33.17%
IPO
-99.98%
Name

Zyversa Therapeutics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-9.41b
L+9,476.43%
-13,199,616-8,905,527-759,097,607-98,297,946-9,413,435,000
CFO
-7.56b
L+86,585.63%
-5,109,833-5,076,089-1,494,641-8,720,819-7,559,697,000

Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
IPO date
Dec 21, 2021
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
9,136,834
14,421
13,023
Unusual Expense (Income)
NOPBT
(9,136,834)
(14,421)
(13,023)
NOPBT Margin
Operating Taxes
(6,745)
(9,456)
745,050
Tax Rate
NOPAT
(9,130,089)
(4,965)
(758,073)
Net income
(9,413,435)
9,476.43%
(98,298)
-87.05%
(759,098)
8,423.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
196,770
7,411
1,865
BB yield
-1,672.31%
-844.58%
-1.31%
Debt
Debt current
9
109
Long-term debt
9
109
Deferred revenue
Other long-term liabilities
850,807
Net debt
(1,530,924)
(3,120)
(5,685)
Cash flow
Cash from operating activities
(7,559,697)
(8,721)
(1,495)
CAPEX
(1)
Cash from investing activities
Cash from financing activities
5,952,947
5,956
FCF
(9,310,549)
17
(759,873)
Balance
Cash
1,530,924
3,138
5,902
Long term investments
Excess cash
1,530,924
3,138
5,902
Stockholders' equity
(112,632,559)
(103,219)
(4,920)
Invested Capital
133,219,890
114,302
104,917
ROIC
ROCE
EV
Common stock shares outstanding
11,100
98
259
Price
1.06
-88.22%
9.00
-98.36%
549.50
 
Market cap
11,766
1,240.85%
878
-99.38%
142,586
 
EV
(1,519,158)
(2,243)
136,901
EBITDA
(9,129,901)
(14,410)
(13,014)
EV/EBITDA
0.17
0.16
Interest
269,856
457
428
Interest/NOPBT